Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Hee Kyoung Jung  (Jung HK) 1 Article
Obesity and Metabolism
Olanzapine-Induced Diabetic Ketoacidosis and Neuroleptic Malignant Syndrome with Rhabdomyolysis: A Case Report
Young Kyoung Sa, Hyeon Yang, Hee Kyoung Jung, Jang Won Son, Seong Su Lee, Seong Rae Kim, Bong Yeon Cha, Ho Young Son, Chi-Un Pae, Soon Jib Yoo
Endocrinol Metab. 2013;28(1):70-75.   Published online March 25, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.1.70
  • 4,118 View
  • 39 Download
  • 7 Crossref
AbstractAbstract PDFPubReader   

Atypical antipsychotics have replaced conventional antipsychotics in the treatment of schizophrenia because they have less of a propensity to cause undesirable neurologic adverse events including extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome (NMS). However, atypical antipsychotics have been known to result in various metabolic complications such as impaired glucose tolerance, diabetes and even diabetic ketoacidosis (DKA). In addition, a number of NMS cases have been reported in patients treated with atypical antipsychotics, although the absolute incidence of neurologic side effects is currently significantly low. Here, we report a patient who simultaneously developed DKA, acute renal failure and NMS with rhabdomyolysis after olanzapine treatment. Olanzapine-induced metabolic complications and NMS were dramatically improved with cessation of the olanzapine treatment and initiation of supportive management including fluid therapy, hemodialysis, and intensive glycemic control using insulin. At short-term follow-up, insulin secretion was markedly recovered as evidenced by a restoration of serum C-peptide level, and the patient no longer required any hypoglycemic medications. Despite the dramatic increase in the use of atypical antipsychotics treatment, individualized treatments along with careful monitoring may be prudent for high risk or vulnerable patients in order to avoid the development of metabolic side effects.

Citations

Citations to this article as recorded by  
  • Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report
    Francesco Piacenza, Suet Kee Ong, Patrick O’Brien, Maurice Clancy
    Clinical Case Reports.2021; 9(4): 2404.     CrossRef
  • Succinylcholine-Induced Rhabdomyolysis in Adults: Case Report and Review of the Literature
    Robert William Barrons, Liem T. Nguyen
    Journal of Pharmacy Practice.2020; 33(1): 102.     CrossRef
  • Improvement in renal prognosis with prompt hemodialysis in hyperosmolar hyperglycemic state-related rhabdomyolysis
    I-Wen Chen, Cheng-Wei Lin
    Medicine.2018; 97(50): e13647.     CrossRef
  • Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication
    Antonia Vuk, Maja Baretic, Martina Matovinovic Osvatic, Igor Filipcic, Nikolina Jovanovic, Martina Rojnic Kuzman
    Journal of Clinical Psychopharmacology.2017; 37(5): 584.     CrossRef
  • A Case of Primary Hypoparathyroidism Presenting with Acute Kidney Injury Secondary to Rhabdomyolysis
    Abdullah Sumnu, Zeki Aydin, Meltem Gursu, Sami Uzun, Serhat Karadag, Egemen Cebeci, Savas Ozturk, Rumeyza Kazancioglu
    Case Reports in Nephrology.2016; 2016: 1.     CrossRef
  • Nanoneurotherapeutics approach intended for direct nose to brain delivery
    Shadab Md, Gulam Mustafa, Sanjula Baboota, Javed Ali
    Drug Development and Industrial Pharmacy.2015; 41(12): 1922.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism